nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—kidney cancer—bone cancer	0.592	1	CtDrD
Everolimus—CYP3A4—bone cancer	0.267	1	CbGaD
Everolimus—MTOR—leg—bone cancer	0.00418	0.204	CbGeAlD
Everolimus—MTOR—forelimb—bone cancer	0.00415	0.202	CbGeAlD
Everolimus—MTOR—hindlimb—bone cancer	0.00373	0.182	CbGeAlD
Everolimus—MTOR—appendage—bone cancer	0.0032	0.156	CbGeAlD
Everolimus—FKBP1A—ALK1 signaling events—TGFBR2—bone cancer	0.00104	0.0296	CbGpPWpGaD
Everolimus—MTOR—connective tissue—bone cancer	0.000913	0.0446	CbGeAlD
Everolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFBR2—bone cancer	0.000878	0.0251	CbGpPWpGaD
Everolimus—FKBP1A—connective tissue—bone cancer	0.000821	0.0401	CbGeAlD
Everolimus—Pimecrolimus—CYP3A4—bone cancer	0.000753	0.349	CrCbGaD
Everolimus—MTOR—tendon—bone cancer	0.000628	0.0306	CbGeAlD
Everolimus—MTOR—bone marrow—bone cancer	0.000608	0.0297	CbGeAlD
Everolimus—MTOR—spinal cord—bone cancer	0.000605	0.0296	CbGeAlD
Everolimus—FKBP1A—TGF-beta receptor signaling—TGFBR2—bone cancer	0.000595	0.017	CbGpPWpGaD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000592	0.0169	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TGFBR2—bone cancer	0.000578	0.0165	CbGpPWpGaD
Everolimus—FKBP1A—tendon—bone cancer	0.000565	0.0276	CbGeAlD
Everolimus—FKBP1A—bone marrow—bone cancer	0.000547	0.0267	CbGeAlD
Everolimus—FKBP1A—spinal cord—bone cancer	0.000545	0.0266	CbGeAlD
Everolimus—MTOR—CXCR4-mediated signaling events—RGS1—bone cancer	0.000527	0.015	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFBR2—bone cancer	0.00052	0.0149	CbGpPWpGaD
Everolimus—Temsirolimus—CYP3A4—bone cancer	0.000509	0.236	CrCbGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—BMI1—bone cancer	0.000504	0.0144	CbGpPWpGaD
Everolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—bone cancer	0.0005	0.0143	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—PTGS2—bone cancer	0.000492	0.0141	CbGpPWpGaD
Everolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFBR2—bone cancer	0.000469	0.0134	CbGpPWpGaD
Everolimus—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000462	0.0132	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—WT1—bone cancer	0.000448	0.0128	CbGpPWpGaD
Everolimus—Tacrolimus—CYP3A4—bone cancer	0.000448	0.208	CrCbGaD
Everolimus—Sirolimus—CYP3A4—bone cancer	0.000448	0.208	CrCbGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000444	0.0127	CbGpPWpGaD
Everolimus—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000435	0.0124	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—MET—bone cancer	0.000377	0.0108	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000349	0.00996	CbGpPWpGaD
Everolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000331	0.00945	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000297	0.00847	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00027	0.00772	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—JUN—bone cancer	0.00027	0.00771	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—SPARC—bone cancer	0.000269	0.00769	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—IGF1R—bone cancer	0.00026	0.00744	CbGpPWpGaD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00025	0.00714	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000246	0.00703	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000243	0.00693	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—BMI1—bone cancer	0.000241	0.00689	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—ATF1—bone cancer	0.000229	0.00654	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CDK4—bone cancer	0.000224	0.0064	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL3—bone cancer	0.000223	0.00638	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—EIF2S1—bone cancer	0.000219	0.00626	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—IGF1R—bone cancer	0.000215	0.00613	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000206	0.00587	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IGF1R—bone cancer	0.000205	0.00586	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—CDK4—bone cancer	0.000201	0.00573	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IGF1R—bone cancer	0.0002	0.0057	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000199	0.00568	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—RB1—bone cancer	0.000195	0.00557	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—bone cancer	0.000191	0.00546	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—JUN—bone cancer	0.000189	0.00541	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IGF1R—bone cancer	0.00018	0.00513	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—BRAF—bone cancer	0.000178	0.00507	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—BRAF—bone cancer	0.000178	0.00507	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—MDM2—bone cancer	0.000175	0.00499	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—RB1—bone cancer	0.000174	0.00498	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—bone cancer	0.000172	0.00491	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000171	0.00489	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—BRAF—bone cancer	0.000169	0.00484	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000165	0.0047	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ATF1—bone cancer	0.000162	0.00462	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—PTGS2—bone cancer	0.00016	0.00458	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—bone cancer	0.000153	0.00437	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000152	0.00436	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—JUN—bone cancer	0.000152	0.00434	CbGpPWpGaD
Everolimus—MTOR—RANKL/RANK Signaling Pathway—JUN—bone cancer	0.00015	0.00427	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—PLAU—bone cancer	0.000146	0.00418	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000143	0.00408	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—MMP9—bone cancer	0.00014	0.00401	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.00014	0.00399	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—KIT—bone cancer	0.000138	0.00393	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—KIT—bone cancer	0.000134	0.00384	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.000133	0.00381	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—KIT—bone cancer	0.000133	0.00381	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—bone cancer	0.00013	0.00372	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—JUN—bone cancer	0.000129	0.00369	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—IGF1R—bone cancer	0.000128	0.00366	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—JUN—bone cancer	0.000126	0.00361	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—JUN—bone cancer	0.000123	0.00352	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—BRAF—bone cancer	0.000122	0.0035	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—BRAF—bone cancer	0.000122	0.0035	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—bone cancer	0.00012	0.00344	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—RB1—bone cancer	0.00012	0.00344	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—bone cancer	0.00012	0.00343	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—EGFR—bone cancer	0.000119	0.00341	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—EZH2—bone cancer	0.000117	0.00335	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—EGFR—bone cancer	0.000114	0.00324	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000113	0.00323	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—bone cancer	0.000111	0.00317	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000109	0.00311	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—MDM2—bone cancer	0.000108	0.0031	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—MDM2—bone cancer	0.000106	0.00302	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—MDM2—bone cancer	0.000105	0.003	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—MMP9—bone cancer	0.000104	0.00296	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000103	0.00296	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KIT—bone cancer	0.000103	0.00294	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ATF1—bone cancer	0.000103	0.00293	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—bone cancer	0.000103	0.00293	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—bone cancer	0.000103	0.00293	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—bone cancer	0.0001	0.00286	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—EGFR—bone cancer	9.92e-05	0.00284	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KIT—bone cancer	9.84e-05	0.00281	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	9.82e-05	0.00281	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KIT—bone cancer	9.69e-05	0.00277	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—bone cancer	9.53e-05	0.00272	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KIT—bone cancer	9.25e-05	0.00264	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KIT—bone cancer	9.21e-05	0.00263	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KIT—bone cancer	9.16e-05	0.00262	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—BRAF—bone cancer	9.16e-05	0.00262	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—GSTP1—bone cancer	9.13e-05	0.00261	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KIT—bone cancer	9.12e-05	0.0026	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—RB1—bone cancer	9e-05	0.00257	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—bone cancer	8.99e-05	0.00257	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—JUN—bone cancer	8.92e-05	0.00255	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—JUN—bone cancer	8.92e-05	0.00255	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—BRAF—bone cancer	8.65e-05	0.00247	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—BRAF—bone cancer	8.65e-05	0.00247	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—bone cancer	8.64e-05	0.00247	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KIT—bone cancer	8.58e-05	0.00245	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	8.58e-05	0.00245	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KIT—bone cancer	8.58e-05	0.00245	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KIT—bone cancer	8.5e-05	0.00243	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KIT—bone cancer	8.43e-05	0.00241	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KIT—bone cancer	8.39e-05	0.0024	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—bone cancer	8.24e-05	0.00235	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bone cancer	8.22e-05	0.00235	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MDM2—bone cancer	8.1e-05	0.00232	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—BRAF—bone cancer	8.06e-05	0.0023	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KIT—bone cancer	7.94e-05	0.00227	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—MDM2—bone cancer	7.75e-05	0.00222	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.72e-05	0.00221	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—bone cancer	7.67e-05	0.00219	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—MDM2—bone cancer	7.63e-05	0.00218	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	7.6e-05	0.00217	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GRM4—bone cancer	7.55e-05	0.00216	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RGS1—bone cancer	7.55e-05	0.00216	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—EGFR—bone cancer	7.41e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—MDM2—bone cancer	7.29e-05	0.00208	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—MDM2—bone cancer	7.25e-05	0.00207	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—bone cancer	7.23e-05	0.00207	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—MDM2—bone cancer	7.22e-05	0.00206	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—MDM2—bone cancer	7.18e-05	0.00205	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—EGFR—bone cancer	7.17e-05	0.00205	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	7.14e-05	0.00204	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	7.08e-05	0.00202	CbGpPWpGaD
Everolimus—Conjunctivitis—Epirubicin—bone cancer	7.07e-05	0.000851	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—bone cancer	7.07e-05	0.000851	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—bone cancer	7.06e-05	0.000849	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—bone cancer	7.06e-05	0.000849	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—bone cancer	7.02e-05	0.000844	CcSEcCtD
Everolimus—Haemoglobin—Methotrexate—bone cancer	7.02e-05	0.000844	CcSEcCtD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bone cancer	7.01e-05	0.002	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—bone cancer	7.01e-05	0.002	CbGpPWpGaD
Everolimus—Haemorrhage—Methotrexate—bone cancer	6.98e-05	0.000839	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—bone cancer	6.98e-05	0.000839	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—bone cancer	6.98e-05	0.000839	CcSEcCtD
Everolimus—FKBP1A—Disease—ENO2—bone cancer	6.95e-05	0.00198	CbGpPWpGaD
Everolimus—Haematuria—Epirubicin—bone cancer	6.94e-05	0.000834	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—bone cancer	6.93e-05	0.000833	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—JUN—bone cancer	6.93e-05	0.00198	CbGpPWpGaD
Everolimus—Urinary tract disorder—Methotrexate—bone cancer	6.89e-05	0.000829	CcSEcCtD
Everolimus—Hepatobiliary disease—Epirubicin—bone cancer	6.88e-05	0.000828	CcSEcCtD
Everolimus—Epistaxis—Epirubicin—bone cancer	6.86e-05	0.000825	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—bone cancer	6.85e-05	0.00196	CbGpPWpGaD
Everolimus—Urethral disorder—Methotrexate—bone cancer	6.84e-05	0.000823	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—bone cancer	6.83e-05	0.000822	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—bone cancer	6.83e-05	0.000821	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—bone cancer	6.81e-05	0.000819	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—bone cancer	6.77e-05	0.000814	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—MDM2—bone cancer	6.76e-05	0.00193	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—MDM2—bone cancer	6.76e-05	0.00193	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	6.76e-05	0.00193	CbGpPWpGaD
Everolimus—Infestation NOS—Doxorubicin—bone cancer	6.73e-05	0.00081	CcSEcCtD
Everolimus—Infestation—Doxorubicin—bone cancer	6.73e-05	0.00081	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—MDM2—bone cancer	6.69e-05	0.00191	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—JUN—bone cancer	6.67e-05	0.00191	CbGpPWpGaD
Everolimus—Hypersensitivity—Cisplatin—bone cancer	6.66e-05	0.000801	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—MDM2—bone cancer	6.64e-05	0.0019	CbGpPWpGaD
Everolimus—Renal failure—Doxorubicin—bone cancer	6.62e-05	0.000796	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDK4—bone cancer	6.62e-05	0.00189	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—MDM2—bone cancer	6.61e-05	0.00189	CbGpPWpGaD
Everolimus—Haemoglobin—Epirubicin—bone cancer	6.57e-05	0.00079	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—bone cancer	6.56e-05	0.000789	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—bone cancer	6.56e-05	0.000789	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—bone cancer	6.55e-05	0.000788	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—bone cancer	6.55e-05	0.000787	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—bone cancer	6.55e-05	0.000787	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—GRM1—bone cancer	6.55e-05	0.00187	CbGpPWpGaD
Everolimus—Hepatitis—Epirubicin—bone cancer	6.53e-05	0.000786	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—bone cancer	6.53e-05	0.000786	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—bone cancer	6.52e-05	0.000784	CcSEcCtD
Everolimus—Hypoaesthesia—Epirubicin—bone cancer	6.5e-05	0.000782	CcSEcCtD
Everolimus—Asthenia—Cisplatin—bone cancer	6.49e-05	0.00078	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.48e-05	0.00185	CbGpPWpGaD
Everolimus—Pharyngitis—Epirubicin—bone cancer	6.48e-05	0.00078	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—bone cancer	6.48e-05	0.000779	CcSEcCtD
Everolimus—Urinary tract disorder—Epirubicin—bone cancer	6.45e-05	0.000776	CcSEcCtD
Everolimus—FKBP1A—Disease—DHFR—bone cancer	6.44e-05	0.00184	CbGpPWpGaD
Everolimus—Oedema peripheral—Epirubicin—bone cancer	6.44e-05	0.000774	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—bone cancer	6.42e-05	0.000772	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—bone cancer	6.42e-05	0.000772	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—bone cancer	6.4e-05	0.00077	CcSEcCtD
Everolimus—Hepatobiliary disease—Doxorubicin—bone cancer	6.37e-05	0.000766	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—JUN—bone cancer	6.37e-05	0.00182	CbGpPWpGaD
Everolimus—Epistaxis—Doxorubicin—bone cancer	6.35e-05	0.000764	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—bone cancer	6.33e-05	0.000762	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—bone cancer	6.32e-05	0.00076	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—bone cancer	6.31e-05	0.000758	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—bone cancer	6.3e-05	0.0018	CbGpPWpGaD
Everolimus—Mediastinal disorder—Methotrexate—bone cancer	6.29e-05	0.000757	CcSEcCtD
Everolimus—Chills—Methotrexate—bone cancer	6.26e-05	0.000753	CcSEcCtD
Everolimus—MTOR—B Cell Activation—MDM2—bone cancer	6.25e-05	0.00179	CbGpPWpGaD
Everolimus—Diarrhoea—Cisplatin—bone cancer	6.18e-05	0.000744	CcSEcCtD
Everolimus—Alopecia—Methotrexate—bone cancer	6.17e-05	0.000742	CcSEcCtD
Everolimus—Mental disorder—Methotrexate—bone cancer	6.12e-05	0.000735	CcSEcCtD
Everolimus—Eye disorder—Epirubicin—bone cancer	6.11e-05	0.000734	CcSEcCtD
Everolimus—Erythema—Methotrexate—bone cancer	6.08e-05	0.000731	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—bone cancer	6.08e-05	0.000731	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—bone cancer	6.08e-05	0.000731	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—bone cancer	6.06e-05	0.000729	CcSEcCtD
Everolimus—Flushing—Epirubicin—bone cancer	6.06e-05	0.000729	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—bone cancer	6.06e-05	0.000729	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—bone cancer	6.05e-05	0.000727	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—bone cancer	6.05e-05	0.000727	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—bone cancer	6.02e-05	0.000723	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—bone cancer	6e-05	0.000721	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	5.98e-05	0.00171	CbGpPWpGaD
Everolimus—Urinary tract disorder—Doxorubicin—bone cancer	5.97e-05	0.000718	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—bone cancer	5.96e-05	0.000716	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—bone cancer	5.95e-05	0.000716	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—bone cancer	5.94e-05	0.000714	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—bone cancer	5.93e-05	0.000713	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—bone cancer	5.93e-05	0.000713	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—bone cancer	5.9e-05	0.00071	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—bone cancer	5.89e-05	0.000708	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bone cancer	5.89e-05	0.00168	CbGpPWpGaD
Everolimus—Back pain—Methotrexate—bone cancer	5.88e-05	0.000707	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	5.87e-05	0.00168	CbGpPWpGaD
Everolimus—Chills—Epirubicin—bone cancer	5.86e-05	0.000705	CcSEcCtD
Everolimus—MTOR—Innate Immune System—ATF1—bone cancer	5.86e-05	0.00167	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KIT—bone cancer	5.84e-05	0.00167	CbGpPWpGaD
Everolimus—Alopecia—Epirubicin—bone cancer	5.77e-05	0.000694	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—RB1—bone cancer	5.75e-05	0.00164	CbGpPWpGaD
Everolimus—Vomiting—Cisplatin—bone cancer	5.75e-05	0.000691	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—bone cancer	5.73e-05	0.000689	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—bone cancer	5.72e-05	0.000688	CcSEcCtD
Everolimus—Rash—Cisplatin—bone cancer	5.7e-05	0.000685	CcSEcCtD
Everolimus—Dermatitis—Cisplatin—bone cancer	5.69e-05	0.000685	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—bone cancer	5.69e-05	0.000684	CcSEcCtD
Everolimus—Erythema—Epirubicin—bone cancer	5.69e-05	0.000684	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—bone cancer	5.65e-05	0.000679	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—bone cancer	5.64e-05	0.000678	CcSEcCtD
Everolimus—Anaemia—Methotrexate—bone cancer	5.62e-05	0.000675	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—bone cancer	5.61e-05	0.000675	CcSEcCtD
Everolimus—Flushing—Doxorubicin—bone cancer	5.61e-05	0.000675	CcSEcCtD
Everolimus—Flatulence—Epirubicin—bone cancer	5.6e-05	0.000674	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—bone cancer	5.57e-05	0.00067	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—bone cancer	5.54e-05	0.00158	CbGpPWpGaD
Everolimus—Back pain—Epirubicin—bone cancer	5.5e-05	0.000661	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—BRAF—bone cancer	5.49e-05	0.00157	CbGpPWpGaD
Everolimus—Angiopathy—Doxorubicin—bone cancer	5.48e-05	0.000659	CcSEcCtD
Everolimus—Malaise—Methotrexate—bone cancer	5.48e-05	0.000659	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—bone cancer	5.47e-05	0.000657	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—bone cancer	5.46e-05	0.000657	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—bone cancer	5.45e-05	0.000655	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—bone cancer	5.44e-05	0.000654	CcSEcCtD
Everolimus—Chills—Doxorubicin—bone cancer	5.42e-05	0.000652	CcSEcCtD
Everolimus—Nausea—Cisplatin—bone cancer	5.37e-05	0.000646	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—bone cancer	5.36e-05	0.000644	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—bone cancer	5.34e-05	0.000642	CcSEcCtD
Everolimus—Cough—Methotrexate—bone cancer	5.3e-05	0.000638	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bone cancer	5.3e-05	0.00151	CbGpPWpGaD
Everolimus—Mental disorder—Doxorubicin—bone cancer	5.3e-05	0.000637	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—bone cancer	5.28e-05	0.000634	CcSEcCtD
Everolimus—Convulsion—Methotrexate—bone cancer	5.27e-05	0.000633	CcSEcCtD
Everolimus—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.27e-05	0.0015	CbGpPWpGaD
Everolimus—Malnutrition—Doxorubicin—bone cancer	5.26e-05	0.000633	CcSEcCtD
Everolimus—Erythema—Doxorubicin—bone cancer	5.26e-05	0.000633	CcSEcCtD
Everolimus—Anaemia—Epirubicin—bone cancer	5.26e-05	0.000632	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bone cancer	5.24e-05	0.0015	CbGpPWpGaD
Everolimus—Agitation—Epirubicin—bone cancer	5.23e-05	0.000628	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—EGFR—bone cancer	5.21e-05	0.00149	CbGpPWpGaD
Everolimus—Flatulence—Doxorubicin—bone cancer	5.19e-05	0.000623	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—bone cancer	5.17e-05	0.000622	CcSEcCtD
Everolimus—Myalgia—Methotrexate—bone cancer	5.17e-05	0.000622	CcSEcCtD
Everolimus—Chest pain—Methotrexate—bone cancer	5.17e-05	0.000622	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—bone cancer	5.15e-05	0.00062	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.14e-05	0.000618	CcSEcCtD
Everolimus—Malaise—Epirubicin—bone cancer	5.13e-05	0.000617	CcSEcCtD
Everolimus—Discomfort—Methotrexate—bone cancer	5.11e-05	0.000615	CcSEcCtD
Everolimus—Syncope—Epirubicin—bone cancer	5.1e-05	0.000613	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—bone cancer	5.09e-05	0.000612	CcSEcCtD
Everolimus—Back pain—Doxorubicin—bone cancer	5.09e-05	0.000612	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—bone cancer	5.06e-05	0.000608	CcSEcCtD
Everolimus—Palpitations—Epirubicin—bone cancer	5.03e-05	0.000604	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—bone cancer	5e-05	0.000601	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—EGFR—bone cancer	4.98e-05	0.00142	CbGpPWpGaD
Everolimus—Cough—Epirubicin—bone cancer	4.96e-05	0.000597	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—bone cancer	4.96e-05	0.000596	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—EGFR—bone cancer	4.96e-05	0.00142	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bone cancer	4.96e-05	0.00142	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—bone cancer	4.93e-05	0.00141	CbGpPWpGaD
Everolimus—Convulsion—Epirubicin—bone cancer	4.93e-05	0.000592	CcSEcCtD
Everolimus—Infection—Methotrexate—bone cancer	4.93e-05	0.000592	CcSEcCtD
Everolimus—Hypertension—Epirubicin—bone cancer	4.91e-05	0.00059	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—EGFR—bone cancer	4.91e-05	0.0014	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MDM2—bone cancer	4.91e-05	0.0014	CbGpPWpGaD
Everolimus—Ill-defined disorder—Doxorubicin—bone cancer	4.88e-05	0.000587	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—bone cancer	4.86e-05	0.000585	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—bone cancer	4.86e-05	0.000585	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—bone cancer	4.86e-05	0.000584	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—bone cancer	4.84e-05	0.000582	CcSEcCtD
Everolimus—Chest pain—Epirubicin—bone cancer	4.84e-05	0.000582	CcSEcCtD
Everolimus—Myalgia—Epirubicin—bone cancer	4.84e-05	0.000582	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bone cancer	4.84e-05	0.00138	CbGpPWpGaD
Everolimus—Agitation—Doxorubicin—bone cancer	4.84e-05	0.000581	CcSEcCtD
Everolimus—Anxiety—Epirubicin—bone cancer	4.83e-05	0.00058	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—bone cancer	4.82e-05	0.000579	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	4.81e-05	0.000578	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—bone cancer	4.8e-05	0.000577	CcSEcCtD
Everolimus—Discomfort—Epirubicin—bone cancer	4.78e-05	0.000575	CcSEcCtD
Everolimus—Malaise—Doxorubicin—bone cancer	4.75e-05	0.000571	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—bone cancer	4.74e-05	0.000569	CcSEcCtD
Everolimus—Anorexia—Methotrexate—bone cancer	4.73e-05	0.000568	CcSEcCtD
Everolimus—Syncope—Doxorubicin—bone cancer	4.72e-05	0.000567	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—bone cancer	4.71e-05	0.000566	CcSEcCtD
Everolimus—FKBP1A—Disease—TGFBR2—bone cancer	4.67e-05	0.00133	CbGpPWpGaD
Everolimus—Palpitations—Doxorubicin—bone cancer	4.65e-05	0.000559	CcSEcCtD
Everolimus—Oedema—Epirubicin—bone cancer	4.64e-05	0.000558	CcSEcCtD
Everolimus—Hypotension—Methotrexate—bone cancer	4.63e-05	0.000557	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—bone cancer	4.63e-05	0.000556	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—EGFR—bone cancer	4.62e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	4.62e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—bone cancer	4.62e-05	0.00132	CbGpPWpGaD
Everolimus—Infection—Epirubicin—bone cancer	4.61e-05	0.000554	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SMO—bone cancer	4.61e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MDM2—bone cancer	4.6e-05	0.00131	CbGpPWpGaD
Everolimus—Cough—Doxorubicin—bone cancer	4.59e-05	0.000552	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—EGFR—bone cancer	4.58e-05	0.00131	CbGpPWpGaD
Everolimus—Shock—Epirubicin—bone cancer	4.57e-05	0.000549	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—bone cancer	4.56e-05	0.000548	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—bone cancer	4.55e-05	0.000547	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—bone cancer	4.54e-05	0.000546	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—bone cancer	4.54e-05	0.000546	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bone cancer	4.53e-05	0.0013	CbGpPWpGaD
Everolimus—Tachycardia—Epirubicin—bone cancer	4.53e-05	0.000545	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—bone cancer	4.52e-05	0.000543	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—EGFR—bone cancer	4.51e-05	0.00129	CbGpPWpGaD
Everolimus—Skin disorder—Epirubicin—bone cancer	4.51e-05	0.000542	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—bone cancer	4.49e-05	0.00054	CcSEcCtD
Everolimus—Insomnia—Methotrexate—bone cancer	4.49e-05	0.000539	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—bone cancer	4.48e-05	0.000539	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—bone cancer	4.48e-05	0.000539	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—bone cancer	4.48e-05	0.000539	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—bone cancer	4.46e-05	0.000537	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—bone cancer	4.45e-05	0.000536	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.45e-05	0.000535	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—bone cancer	4.43e-05	0.000532	CcSEcCtD
Everolimus—Anorexia—Epirubicin—bone cancer	4.42e-05	0.000532	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—bone cancer	4.42e-05	0.000532	CcSEcCtD
Everolimus—Somnolence—Methotrexate—bone cancer	4.41e-05	0.00053	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bone cancer	4.4e-05	0.00126	CbGpPWpGaD
Everolimus—Dry mouth—Doxorubicin—bone cancer	4.38e-05	0.000527	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—bone cancer	4.37e-05	0.000525	CcSEcCtD
Everolimus—Hypotension—Epirubicin—bone cancer	4.34e-05	0.000522	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—bone cancer	4.31e-05	0.000518	CcSEcCtD
Everolimus—Oedema—Doxorubicin—bone cancer	4.29e-05	0.000516	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—bone cancer	4.28e-05	0.000515	CcSEcCtD
Everolimus—Fatigue—Methotrexate—bone cancer	4.28e-05	0.000514	CcSEcCtD
Everolimus—MTOR—B Cell Activation—EGFR—bone cancer	4.27e-05	0.00122	CbGpPWpGaD
Everolimus—Infection—Doxorubicin—bone cancer	4.27e-05	0.000513	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—JUN—bone cancer	4.26e-05	0.00122	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RGS1—bone cancer	4.25e-05	0.00121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GRM4—bone cancer	4.25e-05	0.00121	CbGpPWpGaD
Everolimus—Pain—Methotrexate—bone cancer	4.24e-05	0.00051	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Epirubicin—bone cancer	4.23e-05	0.000508	CcSEcCtD
Everolimus—Shock—Doxorubicin—bone cancer	4.23e-05	0.000508	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—GNA11—bone cancer	4.22e-05	0.00121	CbGpPWpGaD
Everolimus—Nervous system disorder—Doxorubicin—bone cancer	4.21e-05	0.000506	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—bone cancer	4.21e-05	0.000506	CcSEcCtD
Everolimus—Insomnia—Epirubicin—bone cancer	4.2e-05	0.000505	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—bone cancer	4.19e-05	0.000504	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—bone cancer	4.17e-05	0.000502	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—bone cancer	4.17e-05	0.000501	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—bone cancer	4.15e-05	0.000499	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—bone cancer	4.14e-05	0.000498	CcSEcCtD
Everolimus—Somnolence—Epirubicin—bone cancer	4.13e-05	0.000496	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—bone cancer	4.09e-05	0.000492	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	4.09e-05	0.00117	CbGpPWpGaD
Everolimus—Feeling abnormal—Methotrexate—bone cancer	4.09e-05	0.000491	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—bone cancer	4.09e-05	0.000491	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—bone cancer	4.06e-05	0.000488	CcSEcCtD
Everolimus—Decreased appetite—Epirubicin—bone cancer	4.04e-05	0.000485	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—bone cancer	4.01e-05	0.000483	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—bone cancer	4.01e-05	0.000482	CcSEcCtD
Everolimus—Fatigue—Epirubicin—bone cancer	4e-05	0.000481	CcSEcCtD
Everolimus—Pain—Epirubicin—bone cancer	3.97e-05	0.000477	CcSEcCtD
Everolimus—Constipation—Epirubicin—bone cancer	3.97e-05	0.000477	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—bone cancer	3.92e-05	0.000471	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—bone cancer	3.92e-05	0.000471	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ATF1—bone cancer	3.92e-05	0.00112	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.91e-05	0.00047	CcSEcCtD
Everolimus—MTOR—Disease—ENO2—bone cancer	3.91e-05	0.00112	CbGpPWpGaD
Everolimus—Insomnia—Doxorubicin—bone cancer	3.88e-05	0.000467	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—bone cancer	3.86e-05	0.000464	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—bone cancer	3.83e-05	0.00046	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—bone cancer	3.83e-05	0.00046	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IL3—bone cancer	3.82e-05	0.00109	CbGpPWpGaD
Everolimus—Somnolence—Doxorubicin—bone cancer	3.82e-05	0.000459	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—bone cancer	3.8e-05	0.000456	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—bone cancer	3.78e-05	0.000455	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—bone cancer	3.73e-05	0.000449	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—bone cancer	3.71e-05	0.000446	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—bone cancer	3.7e-05	0.000445	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—GRM1—bone cancer	3.68e-05	0.00105	CbGpPWpGaD
Everolimus—Pain—Doxorubicin—bone cancer	3.67e-05	0.000442	CcSEcCtD
Everolimus—Constipation—Doxorubicin—bone cancer	3.67e-05	0.000442	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—bone cancer	3.67e-05	0.000441	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—bone cancer	3.67e-05	0.000441	CcSEcCtD
Everolimus—Hypersensitivity—Methotrexate—bone cancer	3.65e-05	0.000439	CcSEcCtD
Everolimus—MTOR—Disease—DHFR—bone cancer	3.62e-05	0.00104	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—bone cancer	3.56e-05	0.000428	CcSEcCtD
Everolimus—Feeling abnormal—Doxorubicin—bone cancer	3.54e-05	0.000426	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—bone cancer	3.51e-05	0.000422	CcSEcCtD
Everolimus—Pruritus—Methotrexate—bone cancer	3.51e-05	0.000422	CcSEcCtD
Everolimus—Hypersensitivity—Epirubicin—bone cancer	3.42e-05	0.000411	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.41e-05	0.000975	CbGpPWpGaD
Everolimus—MTOR—Immune System—ATF1—bone cancer	3.41e-05	0.000975	CbGpPWpGaD
Everolimus—Body temperature increased—Doxorubicin—bone cancer	3.4e-05	0.000408	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—bone cancer	3.4e-05	0.000408	CcSEcCtD
Everolimus—Diarrhoea—Methotrexate—bone cancer	3.39e-05	0.000408	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.36e-05	0.000961	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KIT—bone cancer	3.33e-05	0.000952	CbGpPWpGaD
Everolimus—Asthenia—Epirubicin—bone cancer	3.33e-05	0.0004	CcSEcCtD
Everolimus—MTOR—Immune System—IL3—bone cancer	3.33e-05	0.00095	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—bone cancer	3.28e-05	0.000395	CcSEcCtD
Everolimus—Dizziness—Methotrexate—bone cancer	3.28e-05	0.000394	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TGFBR2—bone cancer	3.27e-05	0.000934	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KIT—bone cancer	3.2e-05	0.000914	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KIT—bone cancer	3.19e-05	0.00091	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—bone cancer	3.18e-05	0.000382	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—bone cancer	3.16e-05	0.00038	CcSEcCtD
Everolimus—Vomiting—Methotrexate—bone cancer	3.15e-05	0.000379	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—EGFR—bone cancer	3.14e-05	0.000899	CbGpPWpGaD
Everolimus—Rash—Methotrexate—bone cancer	3.13e-05	0.000376	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—bone cancer	3.12e-05	0.000376	CcSEcCtD
Everolimus—Headache—Methotrexate—bone cancer	3.11e-05	0.000374	CcSEcCtD
Everolimus—Asthenia—Doxorubicin—bone cancer	3.08e-05	0.000371	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IGF1R—bone cancer	3.08e-05	0.000879	CbGpPWpGaD
Everolimus—Dizziness—Epirubicin—bone cancer	3.07e-05	0.000369	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—bone cancer	3.04e-05	0.000365	CcSEcCtD
Everolimus—FKBP1A—Disease—BRAF—bone cancer	3e-05	0.000856	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—bone cancer	2.95e-05	0.000355	CcSEcCtD
Everolimus—Nausea—Methotrexate—bone cancer	2.95e-05	0.000354	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—bone cancer	2.94e-05	0.000353	CcSEcCtD
Everolimus—Rash—Epirubicin—bone cancer	2.93e-05	0.000352	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—bone cancer	2.92e-05	0.000352	CcSEcCtD
Everolimus—Headache—Epirubicin—bone cancer	2.91e-05	0.00035	CcSEcCtD
Everolimus—Dizziness—Doxorubicin—bone cancer	2.84e-05	0.000341	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—bone cancer	2.82e-05	0.000804	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—bone cancer	2.76e-05	0.000332	CcSEcCtD
Everolimus—Vomiting—Doxorubicin—bone cancer	2.73e-05	0.000328	CcSEcCtD
Everolimus—Rash—Doxorubicin—bone cancer	2.71e-05	0.000326	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—bone cancer	2.71e-05	0.000325	CcSEcCtD
Everolimus—Headache—Doxorubicin—bone cancer	2.69e-05	0.000324	CcSEcCtD
Everolimus—MTOR—Disease—TGFBR2—bone cancer	2.63e-05	0.00075	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MDM2—bone cancer	2.62e-05	0.00075	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMO—bone cancer	2.59e-05	0.000741	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—bone cancer	2.55e-05	0.000307	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—MDM2—bone cancer	2.52e-05	0.00072	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MDM2—bone cancer	2.51e-05	0.000717	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—bone cancer	2.42e-05	0.000691	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NDUFA12—bone cancer	2.39e-05	0.000683	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNA11—bone cancer	2.37e-05	0.000678	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—JUN—bone cancer	2.28e-05	0.000652	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIT—bone cancer	2.23e-05	0.000638	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ATF1—bone cancer	2.21e-05	0.00063	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL3—bone cancer	2.15e-05	0.000614	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—bone cancer	2.1e-05	0.000599	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NT5C3A—bone cancer	1.98e-05	0.000566	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—bone cancer	1.94e-05	0.000555	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFBR2—bone cancer	1.84e-05	0.000525	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—bone cancer	1.79e-05	0.000512	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—bone cancer	1.79e-05	0.000512	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MDM2—bone cancer	1.76e-05	0.000502	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1R—bone cancer	1.73e-05	0.000494	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—bone cancer	1.72e-05	0.000492	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—bone cancer	1.72e-05	0.00049	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—bone cancer	1.68e-05	0.000481	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—bone cancer	1.53e-05	0.000437	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—bone cancer	1.53e-05	0.000436	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—bone cancer	1.49e-05	0.000425	CbGpPWpGaD
Everolimus—MTOR—Disease—MDM2—bone cancer	1.41e-05	0.000403	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—bone cancer	1.36e-05	0.000389	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—bone cancer	1.33e-05	0.00038	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—bone cancer	1.26e-05	0.000359	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—bone cancer	1.2e-05	0.000343	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—bone cancer	1.18e-05	0.000337	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—bone cancer	1.04e-05	0.000298	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—bone cancer	1.01e-05	0.000288	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—bone cancer	9.88e-06	0.000282	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—bone cancer	9.65e-06	0.000276	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—bone cancer	8.68e-06	0.000248	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—bone cancer	8.59e-06	0.000245	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—bone cancer	8.36e-06	0.000239	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DHFR—bone cancer	8.05e-06	0.00023	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNA11—bone cancer	7.52e-06	0.000215	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—bone cancer	6.75e-06	0.000193	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—bone cancer	5.83e-06	0.000167	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—bone cancer	5.67e-06	0.000162	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—bone cancer	3.02e-06	8.64e-05	CbGpPWpGaD
